Silo Pharma, Inc. announced positive interim data from its dose optimization study of SPU-21 joint homing peptides
for subcutaneous administration of anti-arthritic agents. Silo Pharma is pursuing a development plan utilizing
its liposomal joint homing peptides as a potential therapy for rheumatoid arthritis (RA).á In the most recent phase of this ongoing animal study, tests were conducted to evaluate the disease-suppressive effects of an SPU-21 peptide-guided anti-arthritis drug versus the drug alone. The drug used in the study was dexamethasone (DEX), a corticosteroid used for its anti-inflammatory and immunosuppressant effects. Earlier results of the same study successfully demonstrated that the subcutaneous (SC) route of liposomal administration (small needle injection into shallow soft tissue just under the layer of skin) is well-suited for use in targeted drug delivery of anti-arthritic agents. Silo Pharma is advancing the development of SPU-21 liposomal joint homing peptides in collaboration with the University of Maryland, Baltimore (UMB).